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Introduction
Neuropathic pain is defined as “pain that is initiated or caused 
by a primary lesion or dysfunction in the nervous system”. 
1 Chronic neuropathic pain is relatively common, affecting 
8% of people in the general population.2 Regardless of the 
initiating condition, neuropathic pain is widely recognised as 
one of the most difficult pain syndromes to treat. It presents 
a significant challenge to clinicians as it does not always 
respond to conventional analgesic therapies.3,4 
What causes neuropathic pain?
While nociceptive pain results from a known or obvious 
source, e.g. trauma, cancer metastasis and ischaemia, and 
the source is often easy to identify, neuropathic pain may 
occur in the absence of an identifiable precipitating cause. 
A definitive underlying diagnosis is found in less than 40% 
of patients with peripheral neuropathy and neuropathic 
pain.5
Neuropathic pain is a common complication of cancer, 
diabetes mellitus, degenerative spine disease, infection 
with human immunodeficiency virus and other infectious 
diseases, and has a profound effect on quality of life.6
The disorder can be caused by compression, transection, 
infiltration, ischaemia or metabolic injury to neuronal 
cell bodies. Neuropathic pain may be classified as either 
peripheral or central in origin.7 Examples of each type are 
outlined in Table I.7
Neuropathic pain utilises the same pain pathways as 
nociceptive pain signals. Information regarding intensity, 
quality and location of pain is conveyed to the sensory 
cortex from the somatosensory thalamus. The central 
nervous system utilises descending inhibitory pathways via 
the dorsolateral fasciculus (Lissauer’s tract) of the spinal 
cord and the periaqueductal grey matter to modulate 
transmission of nociceptive stimuli. 8,9 Nociceptive pain 
stimulates a protective mechanism, e.g. removing a hand 
from the hot plate, while neuropathic pain signals no 
imminent danger.10
The operative difference is that neuropathic pain represents 
a delayed, ongoing response to damage that is no 
longer acute, which continues to be expressed as painful 
sensations. Sensory neurons that are damaged by injury, 
disease or drugs produce spontaneous discharges that lead 
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Table I: Examples of types of neuropathic pain
Some common causes of neuropathic pain7
Peripheral nerve lesion or dysfunction Central nerve lesion or 
dysfunction
Painful diabetic neuropathy Central post-stroke pain
Postherpetic neuralgia Multiple sclerosis pain
Postsurgical pain (including post-
mastectomy and phantom limb pain)
Spinal cord injury pain
Complex regional pain syndrome
Trigeminal neuralgia
Chemotherapy-induced neuropathy
Neuropathy secondary to tumour 
infiltration
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to sustained levels of excitability. These ectopic discharges 
begin to “cross talk” with adjacent uninjured nerve fibres, 
resulting in amplification of the pain impulse (peripheral 
sensitisation).10
This hyperexcitability leads to increased transmitter release, 
causing increased response by spinal cord neurons (central 
sensitisation). The process, known as “windup,” accounts 
for the fact that the level of perceived pain is far greater than 
what is expected based on what can be observed.11,12
Identifying neuropathic pain
Multiple symptoms can help lead to a diagnosis of 
neuropathic pain.7 Neuropathic pain sufferers complain 
of numbness, burning or tingling, or a combination. They 
describe electric shock-like, prickly, or pins-and-needles-
type sensations.  Electric shocks, burning, tingling, cold, 
prickling and itching are the most commonly used phrases 
to describe neuropathic pain. Table II lists the symptoms 
and signs that may be present in neuropathic pain.13
Table II: The signs and symptoms of neuropathic pain13
Symptom or sign Description
Allodynia Pain due to nonnoxious stimuli (clothing and 
light touch) when applied to the affected area. It 
may be mechanical (caused by light pressure), 
dynamic (caused by nonpainful movement of 
a stimulus), or thermal (caused by a nonpainful 
warm or cool stimulus)
Anaesthesia Loss of normal sensation to the affected region
Dysesthaesia Spontaneous or evoked unpleasant abnormal 
sensations
Hyperalgesia Exaggerated response to a mildly noxious 
stimulus applied to the affected region
Hyperpathia Delayed and explosive response to a noxious 
stimulus applied to the affected region
Hypoesthaesia Reduction of normal sensation to the affected 
region
Paresthaesias Nonpainful spontaneous abnormal sensations
Phantom pain Pain from a specific site that no longer exists, 
e.g. an amputated limb, or where there  is no 
current injury
Referred pain Occurs in a region remote from the source
The Neuropathy Pain Scale is a specifically designed 
10-question assessment which helps practitioners identify 
neuropathic pain.14
In particular, high scoring for sharp, sensitive, cold and itchy 
characteristics commonly correlates with a diagnosis of 
neuropathic, rather than nociceptive, pain.14
Management of neuropathic pain
Neuropathic pain tends to exhibit a relatively poor response 
to traditional analgesics. 8,15 No cure for neuropathy exists. 
However, palliation of pain, restoration of therapeutic sleep 
and maintenance of function and improvement in overall 
quality of life remain the mainstay of treatment. Treatment 
with anticonvulsants, such as carbamazepine and gaba-
pentin, or antidepressants (particularly amitriptyline), can be 
effective in treating neuropathic pain.16,17
Adequate treatment trials demand a long-term commitment 
from both the patient and the physician.18 Adherence to the 
prescribed agent and adequate time for the trial are needed 
for any regimen to be effective. As with many difficult 
medical problems, a multidisciplinary approach to treatment 
is often the most successful. A multidisciplinary pain relief 
team includes primary care physicians, neurologists, pain 
specialists such as anaesthesiologists or neurosurgeons, 
psychiatrists, psychologists, pastoral counsellors, advanced 
practice nurses and clinical pharmacologists. As always, 
the most important member of this team is the patient.
Medications that are used to treat neuropathic pain 
include over-the-counter analgesics, anticonvulsants, 
tricyclic antidepressants (TCAs), topical anaesthetic 
agents, nonsteroidal anti-inflammatory drugs (NSAIDs), 
antiarrhythmics and opioids.7,15,18 This varied armamentarium 
reflects the heterogeneity of the patient group and the 
different pathophysiological mechanisms that are postulated 
to produce neuropathic pain.
Antidepressants
TCAs are considered to be the first-line treatment for 
neuropathic pain, provided patients do not have any known 
contraindications.19 They are limited by a slow onset of action 
(analgesia in days to weeks), anticholinergic side-effects 
(a dry mouth, blurred vision, confusion or sedation and 
urinary retention), and potential cardiac toxicity. Amitriptyline 
hydrochloride is the most extensively studied of the TCAs. It 
is given in oral doses of 10-25 mg at bedtime. This dose can 
be slowly titrated with escalating doses every 4-7 days. Frail 
and elderly patients may be unable to tolerate therapeutic 
doses because of the sedation.19
The advent of selective serotonin reuptake inhibitors gave 
hope that they could be used to treat chronic pain without 
the concerns of cardiac toxicity and anticholinergic side-
effects. However, results have been disappointing.10 
Duloxetine is recommended when patients cannot tolerate 
TCAs or TCAs have yielded an inadequate response. 
The dose should be started at 60 mg daily and titrated up 
to 120 mg daily as needed. A trial of therapy for up to four 
weeks is recommended. 10
Patients with neuropathic pain are prone to depression, 
drug dependency and insomnia. Interrupted sleep is one 
of the most difficult problems experienced by patients 
with neuropathy. Antidepressants and sedative-hypnotic 
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medications may be prescribed as important adjunctive 
therapy for neuropathy. 10
Anticonvulsants
Anticonvulsants have been used for several years in the 
management of neuropathic pain. They are considered to be 
second-line agents to antidepressants in the management 
of neuropathic pain. 
Gabapentin is structurally related to γ-aminobutyric acid, a 
pain-modulating neurotransmitter that readily crosses the 
blood-brain barrier. It has been studied for the treatment 
of patients with diabetic peripheral neuropathy. Pain relief 
efficacy is similar to that of tricyclic antidepressants, except 
for a shorter onset of action. Gabapentin is often needed in 
relatively high doses to achieve pain relief which can result 
in side-effects such as dizziness and somnolence. An eight-
week trial is recommended.20
Pregabalin is recommended when gabapentin is ineffective. 
Usually a four- to six-week trial is recommended.10
Topical anaesthetic agents
Patients with localised regions of peripheral neuropathy 
may respond well to topical lidocaine hydrochloride 5% 
patches, especially if the region of pain is relatively small 
and circumscribed. Studies have demonstrated the efficacy 
of topical lidocaine. It is safe, easily administered and has 
minimal side-effects. 21,22Unfortunately, these high-dose 
patches are not available in South Africa.
Anti-inflammatory agents
The usefulness of NSAIDs, such as aspirin and ibuprofen, 
for neuropathic pain is limited. Use of NSAIDs should be 
discouraged because of the adverse effects of these drugs 
on renal function. The cyclo-oxyegenase-2 inhibitors have 
been under scrutiny for causing adverse cardiovascular 
events and cannot be recommended for the long-term 
administration that is needed to treat patients with 
neuropathic pain syndromes.10
Opioid analgesics
In response to severe or persistent pain, interneurons in 
the dorsal horn release endogenous opioids that work to 
reduce perceived pain. These endogenous substances 
(enkephalins, endorphins and dynorphins) play a major 
role in the mechanism of pain reduction and modulation by 
preventing transmission of pain signals to higher centres. 
Exogenously administered opioids mimic the effect of 
enkephalin and dynorphin at mu-type opioid receptors 
which occur throughout the brain and spinal cord.  This 
mechanism accounts for the efficacy of opioid analgesics in 
neuropathic pain syndromes.23
Tramadol hydrochloride, a semisynthetic opioid analgesic, 
may also affect neuropathic pain by low-affinity binding 
to mu receptors. It may also do so by weakly inhibiting 
norepinephrine and serotonin reuptake, mirroring the 
mechanism of action of both opioids and TCAs. One trial 
suggests that tramadol may be better tolerated than TCAs 
in some individuals with diabetic peripheral neuropathy or 
other neuropathic pain syndromes.24
Because of concerns about tolerance, abuse and addiction, 
the use of opioids in treating nonmalignant pain was 
formerly considered to be controversial. However, in recent 
years, considerable research has supported the use of 
these agents. Neuropathic pain is now treated with opioids 
commonly and effectively.15,19,25-27
Combined therapy
Clinical experience supports the use of more than one agent 
to treat patients with refractory neuropathic pain. Because 
there may be several physiological mechanisms that cause 
pain, the use of more than one type of medication may be 
necessary. 
While monotherapy may be desirable, both for ease of 
administration and the reduction of potential side-effects, 
this approach may not achieve satisfactory pain relief. The 
strategy of using two or more agents at lower doses to 
achieve synergistic pain efficacy is an effective one.19,28,29 
The most widely studied combination is gabapentin used 
with morphine to manage neuropathic pain.19 It was found to 
be more effective than either agent used alone, suggesting 
that combination treatment strategies offer synergistic pain 
control.
Managing neuropathic pain 
It is particularly important that patients with neuropathic pain 
are identified in primary care and managed appropriately 
according to their individual treatment needs. Patients 
with neuropathic pain often don’t respond to commonly 
used analgesics and require ongoing treatment that targets 
the underlying mechanisms that are responsible for the 
sensitisation and the experience of pain. 
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